REPORT ID 2232

Global Myasthenia Gravis Drugs Market Research Report 2017

Publish Date
8-Dec-17
Pages
117
Format
Electronic (PDF)

In this report, the global Myasthenia Gravis Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Myasthenia Gravis Drugs in these regions, from 2012 to 2022 (forecast), covering
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
Global Myasthenia Gravis Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
    Pfizer
    Shire
    Flamel Technologies
    F. Hoffmann-La Roche
    Grifols
    Valeant Pharmaceuticals
    GlaxoSmithKline
    Novartis
    Mitsubishi Tanabe Pharma
    Cytokinetics
    Lupin Pharmaceuticals
    CSL Group
    Alexion Pharmaceuticals
    Catalyst Pharmaceuticals
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Anticholinesterases
    Immunosuppressants
    Intravenous Immune Globulins
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
    Hospitals
    Clinics
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global Myasthenia Gravis Drugs Market Research Report 2017
1 Myasthenia Gravis Drugs Market Overview
    1.1 Product Overview and Scope of Myasthenia Gravis Drugs
    1.2 Myasthenia Gravis Drugs Segment by Type (Product Category)
        1.2.1 Global Myasthenia Gravis Drugs Production and CAGR (%) Comparison by Type (Product Category)(2012-2022)
        1.2.2 Global Myasthenia Gravis Drugs Production Market Share by Type (Product Category) in 2016
        1.2.3 Anticholinesterases
        1.2.4 Immunosuppressants
        1.2.5 Intravenous Immune Globulins
    1.3 Global Myasthenia Gravis Drugs Segment by Application
        1.3.1 Myasthenia Gravis Drugs Consumption (Sales) Comparison by Application (2012-2022)
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Other
    1.4 Global Myasthenia Gravis Drugs Market by Region (2012-2022)
        1.4.1 Global Myasthenia Gravis Drugs Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
        1.4.2 North America Status and Prospect (2012-2022)
        1.4.3 Europe Status and Prospect (2012-2022)
        1.4.4 China Status and Prospect (2012-2022)
        1.4.5 Japan Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Status and Prospect (2012-2022)
        1.4.7 India Status and Prospect (2012-2022)
    1.5 Global Market Size (Value) of Myasthenia Gravis Drugs (2012-2022)
        1.5.1 Global Myasthenia Gravis Drugs Revenue Status and Outlook (2012-2022)
        1.5.2 Global Myasthenia Gravis Drugs Capacity, Production Status and Outlook (2012-2022)

2 Global Myasthenia Gravis Drugs Market Competition by Manufacturers
    2.1 Global Myasthenia Gravis Drugs Capacity, Production and Share by Manufacturers (2012-2017)
        2.1.1 Global Myasthenia Gravis Drugs Capacity and Share by Manufacturers (2012-2017)
        2.1.2 Global Myasthenia Gravis Drugs Production and Share by Manufacturers (2012-2017)
    2.2 Global Myasthenia Gravis Drugs Revenue and Share by Manufacturers (2012-2017)
    2.3 Global Myasthenia Gravis Drugs Average Price by Manufacturers (2012-2017)
    2.4 Manufacturers Myasthenia Gravis Drugs Manufacturing Base Distribution, Sales Area and Product Type
    2.5 Myasthenia Gravis Drugs Market Competitive Situation and Trends
        2.5.1 Myasthenia Gravis Drugs Market Concentration Rate
        2.5.2 Myasthenia Gravis Drugs Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Myasthenia Gravis Drugs Capacity, Production, Revenue (Value) by Region (2012-2017)
    3.1 Global Myasthenia Gravis Drugs Capacity and Market Share by Region (2012-2017)
    3.2 Global Myasthenia Gravis Drugs Production and Market Share by Region (2012-2017)
    3.3 Global Myasthenia Gravis Drugs Revenue (Value) and Market Share by Region (2012-2017)
    3.4 Global Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.5 North America Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.6 Europe Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.7 China Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.8 Japan Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.9 Southeast Asia Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.10 India Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Myasthenia Gravis Drugs Supply (Production), Consumption, Export, Import by Region (2012-2017)
    4.1 Global Myasthenia Gravis Drugs Consumption by Region (2012-2017)
    4.2 North America Myasthenia Gravis Drugs Production, Consumption, Export, Import (2012-2017)
    4.3 Europe Myasthenia Gravis Drugs Production, Consumption, Export, Import (2012-2017)
    4.4 China Myasthenia Gravis Drugs Production, Consumption, Export, Import (2012-2017)
    4.5 Japan Myasthenia Gravis Drugs Production, Consumption, Export, Import (2012-2017)
    4.6 Southeast Asia Myasthenia Gravis Drugs Production, Consumption, Export, Import (2012-2017)
    4.7 India Myasthenia Gravis Drugs Production, Consumption, Export, Import (2012-2017)

5 Global Myasthenia Gravis Drugs Production, Revenue (Value), Price Trend by Type
    5.1 Global Myasthenia Gravis Drugs Production and Market Share by Type (2012-2017)
    5.2 Global Myasthenia Gravis Drugs Revenue and Market Share by Type (2012-2017)
    5.3 Global Myasthenia Gravis Drugs Price by Type (2012-2017)
    5.4 Global Myasthenia Gravis Drugs Production Growth by Type (2012-2017)

6 Global Myasthenia Gravis Drugs Market Analysis by Application
    6.1 Global Myasthenia Gravis Drugs Consumption and Market Share by Application (2012-2017)
    6.2 Global Myasthenia Gravis Drugs Consumption Growth Rate by Application (2012-2017)
    6.3 Market Drivers and Opportunities
        6.3.1 Potential Applications
        6.3.2 Emerging Markets/Countries

7 Global Myasthenia Gravis Drugs Manufacturers Profiles/Analysis
    7.1 Pfizer
        7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.1.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.1.2.1 Product A
            7.1.2.2 Product B
        7.1.3 Pfizer Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.1.4 Main Business/Business Overview
    7.2 Shire
        7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.2.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.2.2.1 Product A
            7.2.2.2 Product B
        7.2.3 Shire Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.2.4 Main Business/Business Overview
    7.3 Flamel Technologies
        7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.3.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.3.2.1 Product A
            7.3.2.2 Product B
        7.3.3 Flamel Technologies Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.3.4 Main Business/Business Overview
    7.4 F. Hoffmann-La Roche
        7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.4.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.4.2.1 Product A
            7.4.2.2 Product B
        7.4.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.4.4 Main Business/Business Overview
    7.5 Grifols
        7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.5.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.5.2.1 Product A
            7.5.2.2 Product B
        7.5.3 Grifols Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.5.4 Main Business/Business Overview
    7.6 Valeant Pharmaceuticals
        7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.6.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.6.2.1 Product A
            7.6.2.2 Product B
        7.6.3 Valeant Pharmaceuticals Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.6.4 Main Business/Business Overview
    7.7 GlaxoSmithKline
        7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.7.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.7.2.1 Product A
            7.7.2.2 Product B
        7.7.3 GlaxoSmithKline Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.7.4 Main Business/Business Overview
    7.8 Novartis
        7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.8.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.8.2.1 Product A
            7.8.2.2 Product B
        7.8.3 Novartis Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.8.4 Main Business/Business Overview
    7.9 Mitsubishi Tanabe Pharma
        7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.9.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.9.2.1 Product A
            7.9.2.2 Product B
        7.9.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.9.4 Main Business/Business Overview
    7.10 Cytokinetics
        7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.10.2 Myasthenia Gravis Drugs Product Category, Application and Specification
            7.10.2.1 Product A
            7.10.2.2 Product B
        7.10.3 Cytokinetics Myasthenia Gravis Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.10.4 Main Business/Business Overview
    7.11 Lupin Pharmaceuticals
    7.12 CSL Group
    7.13 Alexion Pharmaceuticals
    7.14 Catalyst Pharmaceuticals

8 Myasthenia Gravis Drugs Manufacturing Cost Analysis
    8.1 Myasthenia Gravis Drugs Key Raw Materials Analysis
       8.1.1 Key Raw Materials
       8.1.2 Price Trend of Key Raw Materials
       8.1.3 Key Suppliers of Raw Materials
       8.1.4 Market Concentration Rate of Raw Materials
    8.2 Proportion of Manufacturing Cost Structure
       8.2.1 Raw Materials
       8.2.2 Labor Cost
       8.2.3 Manufacturing Expenses
    8.3 Manufacturing Process Analysis of Myasthenia Gravis Drugs

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
    9.1 Myasthenia Gravis Drugs Industrial Chain Analysis
    9.2 Upstream Raw Materials Sourcing
    9.3 Raw Materials Sources of Myasthenia Gravis Drugs Major Manufacturers in 2015
    9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
    10.1 Marketing Channel
        10.1.1 Direct Marketing
        10.1.2 Indirect Marketing
        10.1.3 Marketing Channel Development Trend
    10.2 Market Positioning
        10.2.1 Pricing Strategy
        10.2.2 Brand Strategy
        10.2.3 Target Client
    10.3 Distributors/Traders List

11 Market Effect Factors Analysis
    11.1 Technology Progress/Risk
        11.1.1 Substitutes Threat
        11.1.2 Technology Progress in Related Industry
    11.2 Consumer Needs/Customer Preference Change
    11.3 Economic/Political Environmental Change

12 Global Myasthenia Gravis Drugs Market Forecast (2017-2022)
    12.1 Global Myasthenia Gravis Drugs Capacity, Production, Revenue Forecast (2017-2022)
        12.1.1 Global Myasthenia Gravis Drugs Capacity, Production and Growth Rate Forecast (2017-2022)
        12.1.2 Global Myasthenia Gravis Drugs Revenue and Growth Rate Forecast (2017-2022)
        12.1.3 Global Myasthenia Gravis Drugs Price and Trend Forecast (2017-2022)
    12.2 Global Myasthenia Gravis Drugs Production, Consumption , Import and Export Forecast by Region (2017-2022)
        12.2.1 North America Myasthenia Gravis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.2 Europe Myasthenia Gravis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.3 China Myasthenia Gravis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.4 Japan Myasthenia Gravis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.5 Southeast Asia Myasthenia Gravis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.6 India Myasthenia Gravis Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
    12.3 Global Myasthenia Gravis Drugs Production, Revenue and Price Forecast by Type (2017-2022)
    12.4 Global Myasthenia Gravis Drugs Consumption Forecast by Application (2017-2022)

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology/Research Approach
        14.1.1 Research Programs/Design
        14.1.2 Market Size Estimation
        14.1.3 Market Breakdown and Data Triangulation
    14.2 Data Source
        14.2.1 Secondary Sources
        14.2.2 Primary Sources
    14.3 Disclaimer